A study demonstrated that TP53 mutations were associated with immune activation in NSCLC, and DNA damage repair gene mutations play an important role in upregulating the expression of PD-L1, which might be therapeutic targets for combination therapies with ICIs [133,134]. Here, TP53 is linked to non-small cell lung carcinoma.